ABVC BIOPHARMA, INC. Operating Income Loss

• ABVC BIOPHARMA, INC. showed a decrease of -52.0% in Operating Income Loss from 2024 to 2025.
• This data is from ABVC BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
• XBRL data for this metric is available from 2011 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2011 to 2025), ABVC BIOPHARMA, INC.'s Operating Income Loss has declined by 278.8%.
• Historical annual values: Fiscal year 2025: -$7.15 million | Fiscal year 2024: -$4.71 million | Fiscal year 2023: -$6.77 million | Fiscal year 2022: -$15.11 million | Fiscal year 2021: -$11.71 million | Fiscal year 2020: -$8.51 million | Fiscal year 2019: -$3.46 million | Fiscal year 2018: -$2.78 million | Fiscal year 2017: -$4.14 million | Fiscal year 2017: -$4.00 million | Fiscal year 2016: -$11.00 million | Fiscal year 2013: -$177.3 thousand | Fiscal year 2012: -$1.14 million | Fiscal year 2011: -$1.89 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026